Suffering from dermatitis? How to find relief this winter
With the help of prescription medications and a whole lot of moisturizing, it’s possible to keep dermatitis under control.
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...
Hosted on MSN1d
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
Monthly Prescribing Reference5d
Rezpegaldesleukin Fast Tracked for Moderate to Severe Atopic Dermatitis
Rezpegaldesleukin is currently being investigated in the phase 2b REZOLVE-AD study (ClinicalTrials.gov Identifier: NCT06136741) in 398 adult patients with moderate to severe atopic dermatitis who ...
Pharmabiz4d
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...
Managed Healthcare Executive11d
Tapinarof Cream Improves Symptoms and Quality of Life in Children with Severe Atopic Dermatitis
Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...
Managing Eczema Symptoms: Indoor And Outdoor Environments Have Different Triggers
Your indoor versus outdoor environment could have an even bigger impact on your eczema symptoms than you realize.
FiercePharma5d
Incyte's JAK cream Opzelura picks up steam as company works to revive Jakafi XR dreams
Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...
The American Journal of Managed Care4d
AI-Enabled Wearable Sensor Reduces Scratching in Atopic Dermatitis
Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...